Total Ongoing Charges
Please note that whilst we endeavour to show all charges associated with specific funds, sometimes this is not possible due to the information
not being made available by the fund provider. In such cases transaction or incidental cost information may be missing.
Worldwide Healthcare Trust invests in Healthcare and Biotechnology firms on a global basis. It owns a relatively diversified portfolio of 60-70 companies which are mainly owned and based in the US, with the objective of delivering capital growth to investors over the long term. The managers of the Trust, OrbiMed Capital, are based in New York and are one of the leaders in the field of healthcare and biotechnology investment. The depth of resource upon which they can draw in terms of medical and investment expertise, longevity of investing in the sector and network of industry contacts is extremely impressive. In order to achieve its investment objective, the Company invests in a diversified portfolio of shares in pharmaceutical and biotechnology companies and related securities in the healthcare sector on a worldwide basis. It uses gearing and can use derivative transactions to mitigate risk and also to enhance capital returns.
Worldwide Healthcare Trust PLC is an investment trust. The Trust invests in the global healthcare sector with the objective of achieving a high level of capital growth. The Trust invests in a diversified portfolio of shares in pharmaceutical and biotechnology companies and related securities in the healthcare sector. The Trust uses gearing and derivative transactions. The Trust invests approximately 60% of the portfolio in larger companies, and at over 20% of the portfolio in smaller companies. Its investment strategies also maintains that over 5% of the portfolio, at the time of acquisition, may be invested in each of debt instruments, convertibles and royalty bonds issued by pharmaceutical and biotechnology companies. It may invest over of 20% of the portfolio, at the time of acquisition, in companies under sectors, such as healthcare equipment and supplies, healthcare technology, and healthcare providers and services. OrbiMed Capital LLC is the portfolio manager of the Trust.
BRIEF: For the six months ended 30 September 2018, Worldwide Healthcare Trust PLC revenues increased from £97.9M to £241.9M. Net income increased from £81.7M to £240.5M. Revenues reflect Gains on investments increase from £84.7M to £238.5M, Income from investments increase of 46% to £8.1M. Dividend per share remained flat at £0.07. Basic Earnings per Share excluding Extraordinary Items increased from £1.75 to £4.80.
Add a sector as a comparatorAdd an index as a comparatorAdd a share as a comparator
Add a moving average as a comparatorAdd a lower indicator as a comparatorChart StyleCurrent Comparators
Headline performance can mask the true characteristics of a fund. Without fully understanding how a fund is managed, you may inadvertanly become exposed to an undesirable level of risk to your capital. Some funds carry a dilution levy which reduces the number of units realised on any initial investment as an initial charge. If this fund carries such a levy it should be detailed in the Key Investor Information Document (KIID), which we must provide and you should read before investing.
The graphs shown are supplied by an external data provider and may contain data that appears to preced the introduction of the clean unit class for this fund. In such cases, historial data has been synthesised at the entire discretion of that external provider as realistically as possible using historical data recorded against the previously available commission-paying version of the fund, adjusting for fees in the process.
The documents listed below are the latest versions made available to our data provider by the fund management group, but may not necessarily reflect the applicable charges that would be levied should you purchase this fund via Charles Stanley Direct. You should treat the charges and other figures shown in the 'Overview' tab as accurate.
Fund Provider Factsheet
The Fact Sheet is supplied on a monthly basis by the management group and provides limited information on the fund. Past performance data and a review of how the fund has performed are commonly featured.
Key Information Document
This document, issued by the product provider, provides key information about an investment product. The information is required by law to help potential investors understand the nature, risks, costs, potential gains and losses of the product and enable comparison with other products.
A report published by the Fund Management Group detailing the progress of the fund during the course of the previous 12 months. The information provided includes a financial statement for the group as a whole.
2,502,975 bytes PDF Document; last updated 31 Mar 2018
Semi Annual Report
Published periodically through the course of the financial year of the fund, the report provides an overview of the fund's performance and the prospects for the remainder of the year. Included are portfolio changes (i.e. which stocks have been bought and sold), and changes in the geographical breakdown during the course of the previous 12 months.
has managed this fund for 0 months.
Trevor M. Polischuk, Ph.D., is a Public Equity Partner focused on the global pharmaceutical industry. Previously, he worked at Lehman Brothers as a Senior Research Analyst covering the U.S. pharmaceutical industry. Dr. Polischuk began his career at Warner Lambert as a member of the Pharmaceutical Global Marketing Planning team. In this role, he coordinated marketing activities for the second generation gabapentinoid product, Pregabalin. Dr. Polischuk holds a Doctorate in Neuropharmacology & Gross Human Anatomy from Queen's University and an M.B.A. from Queen's University.
Manager Cumulative Performance v Peer Group
Sven H Borho
has managed this fund for 23 years and 7 months.
Sven H. Borho CFA, is a founding Partner of OrbiMed. Mr. Borho is a senior member of the public equity team and he is a portfolio manager for OrbiMed's public equity and hedge funds. Mr. Borho has played an integral role in the growth of OrbiMed's asset management activities. Mr. Borho started his career in 1991 when he joined OrbiMed's predecessor firm as a Senior Analyst covering European pharmaceutical firms and biotechnology companies worldwide. Mr. Borho studied business administration at Bayreuth University in Germany and received an M.Sc. (Econ.), Accounting and Finance, from The London School of Economics; he is a citizen of both Germany and Sweden.
Manager Cumulative Performance v Peer Group
Income Statement - All values are in GBP (M).
Profit Before Tax
Profit After Tax
Equity Holders of Parent Company
Balance Sheet - All values are in GBP (M).
Total Non-Current Assets
Total Current Assets
Total Net Assets
The value of investments can fall as well as rise. Investors may get back less than invested. Past performance is not a reliable guide to future returns.
Please contact us if you have any questions.